Regional brain metabolism in schizophrenia: The influence of antipsychotics.
BACKGROUND
Schizophrenia has been associated with a plethora of metabolic changes in the brain that vary with duration and type of psychoses. Additionally, it has been observed that antipsychotics can further alter cerebral glucose metabolism. These changes resulting from antipsychotics have been postulated to be reflective of the duration and mechanism of action of the medication.


OBJECTIVE
We aimed to examine the influence of antipsychotics on brain metabolism in individuals with schizophrenia in a naturalistic setting.


METHODS
A cross-sectional study was carried out by the psychiatry department of a tertiary care hospital in collaboration with the Radiation Medicine Centre.


METHODS
Eighteen male patients with schizophrenia in different phases of treatment underwent an 18F-deoxyglucose positron emission tomography scan in a resting state 12 hours after the last dose of antipsychotic.


METHODS
The types and duration of treatment were then compared with the regional glucose uptake in 14 predetermined regions of interest. The relative Uptake Values were further compared using SPSS 11.0.


RESULTS
An immediate increase followed by a decrease in cortical uptake was noted while the basal ganglia uptake remained high, albeit with a decreasing trend. Typical antipsychotics were associated with lower frontal cortical and higher basal ganglia and cerebellar uptake as compared to atypical antipsychotics.


CONCLUSIONS
The differential influence of the type and duration of antipsychotic on glucose uptake suggests a possible trend towards long-term side effects with typical medications that were not noted on clinical examination. This however needs to be confirmed with larger, controlled studies.
Seethalakshmi
R
R
Department of Psychiatry, KEM Hospital and Seth GS Medical College, Mumbai, India. drseetha.r@gmail.com
Parkar
S R
SR
Nair
N
N
Batra
S A
SA
Pandit
A G
AG
Adarkar
S A
SA
Baghel
N S
NS
Moghe
S H
SH
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D003430:Cross-Sectional Studies; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*
D014150:Antipsychotic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18